Anteris Technologies Global Corp. (“ATGC”) today announced that
it has launched the roadshow for its proposed initial public
offering of 14,800,000 shares of its common stock (“Common Stock”)
in the U.S. (the “Offering”). All shares of Common Stock to be sold
in the Offering will be offered by ATGC. In addition, ATGC intends
to grant the underwriters a 30-day option to purchase up to an
additional 2,220,000 shares of Common Stock from ATGC at the
initial public offering price, less underwriting discounts and
commissions. ATGC has applied to list the Common Stock on the
Nasdaq Global Market under the ticker symbol “AVR.”
ATGC intends to use the net proceeds to it from the Offering,
together with its existing cash and cash equivalents, primarily for
the ongoing development of its DurAVR® transcatheter heart valve
(“DurAVR® THV”) and the preparation and enrollment of a randomized
global pivotal study of DurAVR® THV for treating severe aortic
stenosis, with the remaining for working capital and other general
corporate purposes determined from time to time, including the
repayment of amounts owed under its convertible note facility. TD
Cowen, Barclays and Cantor are acting as joint book-running
managers for the proposed Offering, with Lake Street Capital
Markets acting as lead manager.
Following the Offering, ATGC intends to list its CHESS
Depositary Interests (“CDIs”) (representing underlying shares of
Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the
Australian Securities Exchange (“ASX”) under the symbol “AVR.”
The proposed Offering will be made only by means of a
prospectus. Copies of the preliminary prospectus relating to the
Offering, when available, may be obtained from: TD Securities (USA)
LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at
(855) 495-9846 or by e-mail at TD.ECM_Prospectus@tdsecurities.com;
Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue Edgewood, NY 11717, by telephone at (888)
603-5847 or by e-mail at Barclaysprospectus@broadridge.com; or
Cantor Fitzgerald & Co., 110 East 59th Street, 6th Floor, New
York, NY 10022, by telephone at (212) 915-1800 or by e-mail at
prospectus@cantor.com.
A registration statement on Form S-1 relating to the Common
Stock has been filed with the Securities and Exchange Commission
but has not yet become effective. These securities may not be sold,
nor may offers to buy be accepted, prior to the time the
registration statement becomes effective. This press release is for
informational purposes only and does not constitute an offer to
sell or the solicitation of an offer to buy any securities, and
shall not constitute an offer, solicitation or sale of securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. As disclosed
in the registration statement, the underwriters may engage in
stabilizing actions or related activities in connection with the
Offering.
About ATGC
ATGC was incorporated on January 29, 2024 for the purpose of
reorganizing the operations of Anteris Technologies Ltd
(“Anteris”), an Australian public company originally registered in
Western Australia, Australia and listed on the ASX, into a
structure whereby the ultimate parent company will be a Delaware
corporation.
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart
company committed to designing, developing, and commercializing
innovative medical devices. Founded in Australia, with a
significant presence in Minneapolis, USA (a MedTech hub), Anteris
is science-driven, with an experienced team of multidisciplinary
professionals delivering potentially transformative solutions to
structural heart disease patients.
Anteris’ lead product, DurAVR®, is a transcatheter heart valve
for treating aortic stenosis. It is the first transcatheter aortic
valve replacement to use a single piece of bioengineered tissue.
This biomimetic valve is uniquely shaped to mimic the performance
of a healthy human aortic valve.
DurAVR® THV is made using ADAPT® tissue, Anteris’ patented
anti-calcification tissue technology. ADAPT® tissue has been used
clinically for over 10 years and distributed for use in over 55,000
patients worldwide.
The ComASUR® Delivery System was designed to provide controlled
deployment and accurate placement of the DurAVR® THV with
balloon-expandable delivery, designed to achieve precise alignment
with the heart’s native commissures to achieve ideal valve
positioning.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include all statements that are not
historical facts. Forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,”
“strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,”
“should,” “could,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements include any statements regarding the
Offering, commencement of trading of the Common Stock on Nasdaq and
the CDIs on the ASX, the anticipated use of the net proceeds of the
Offering, and that the underwriters may engage in stabilizing
actions or related activities in connection with the Offering.
These forward-looking statements, including statements regarding
the size of the Offering, are subject to a number of risks,
uncertainties, and assumptions, including those described under
“Risk Factors” in ATGC’s registration statement relating to the
Offering. Readers are cautioned not to put undue reliance on
forward-looking statements, and except as required by law, neither
ATGC or Anteris assume any obligation to update any of these
forward-looking statements to conform these statements to actual
results or revised expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241208278074/en/
Investor Relations investors@anteristech.com Anteris
Technologies Ltd +61 1300 550 310 | +61 7 3152 3200
Investor Relations (US) Malini Chatterjee, Ph.D.
Blueprint Life Science Group +1 917 330 4269
Avaron Mining (TSXV:AVR)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Avaron Mining (TSXV:AVR)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
